What is the Travere Therapeutics Inc. stock price forecast?

Travere Therapeutics Inc. is currently trading at $42.13. View real-time AI analysis on Alpha Lenz.

What is Travere Therapeutics Inc. insider trading activity?

View the latest insider trading data for Travere Therapeutics Inc. on Alpha Lenz.

What is Travere Therapeutics Inc.'s P/E ratio?

Travere Therapeutics Inc.'s P/E ratio is -10.3.

Travere Therapeutics Inc.

NASDAQ · TVTX

$42.13

Ask about Travere Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Travere Therapeutics Inc. trades at a P/E of -10.3 (undervalued) with modest ROE of -247.4%. 3Y revenue CAGR of 20.9% highlights clear growth momentum.”

Ask for details →

Company Overview

Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases. The company's primary mission is to address unmet medical needs in patient populations that have few existing treatment options. Travere Therapeutics operates in the pharmaceutical sector, focusing predominantly on nephrology and hepatology. Its pipeline includes drug candidates aimed at treating complex conditions like focal segmental glomerulosclerosis (FSGS) and Alport syndrome, both of which are linked to kidney diseases. With a strong commitment to advancing scientific research and improving patient outcomes, Travere Therapeutics partners with healthcare professionals and scientists to drive innovation in niche medical areas. The company plays a significant role in the biotech industry, providing new avenues for treating challenging health issues that affect small populations. Travere's presence in the rare disease market underscores its significance as a leader in providing hope and solutions for patients who desperately need breakthrough therapeutics.

CEODr. Eric M. Dube Ph.D.

Websitehttps://www.travere.com

SectorHealthcare

IndustryBiotechnology

Employees385

Company Statistics

FY 2024

Profile

$3.32BMarket Cap

$233.18MRevenue

0.00Shares Out

385Employees

Margins

96.68%Gross

-112.93%EBITDA

-137.83%Operating

-137.45%Pre-Tax

-137.90%Net

Valuation

-10.34P/E

56.26P/B

14.25EV/Sales

-13.92EV/EBITDA

-9.81P/FCF

Growth (CAGR)

20.93%Rev 3Yr

5.87%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-46.50%ROA

-247.45%ROE

-44.73%ROIC

Financial Health

$58.53MCash & Cash Equivalents

$476.51MNet Debt

905.68%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Travere Therapeutics Inc. trades at a P/E of -10.3 (undervalued) with modest ROE of -247.4%. 3Y revenue CAGR of 20.9% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Travere Therapeutics Inc. (ticker: TVTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 385 employees. Market cap is $3.3B.

The current price is $42.13 with a P/E ratio of -10.34x and P/B of 56.26x.

ROE is -247.45% and operating margin is -137.83%. Annual revenue is $233M.